Elevance Health CarelonRx — Cost of products sold decreased by 8.1% to $9.83B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.9%, from $9.28B to $9.83B. Over 3 years (FY 2022 to FY 2025), CarelonRx — Cost of products sold shows an upward trend with a 14.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Rising costs relative to revenue may indicate supply chain inflation or unfavorable drug pricing, while stable or falling costs suggest effective procurement and supply chain management.
The direct costs associated with the procurement and distribution of pharmaceutical products sold by the CarelonRx segme...
Comparable to cost of goods sold (COGS) for pharmacy retail or mail-order operations at major pharmacy benefit managers.
elv_segment_carelonrx_cost_of_products_sold| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.64B | $6.64B | $6.64B | $6.64B | $7.90B | $7.90B | $7.90B | $7.90B | $7.37B | $8.04B | $8.34B | $9.23B | $9.28B | $9.88B | $10.21B | $10.70B | $9.83B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +19.0% | +0.0% | +0.0% | +0.0% | -6.6% | +9.0% | +3.7% | +10.7% | +0.6% | +6.5% | +3.3% | +4.8% | -8.1% |
| YoY Change | — | — | — | — | +19.0% | +19.0% | +19.0% | +19.0% | -6.6% | +1.8% | +5.6% | +16.9% | +25.9% | +22.9% | +22.5% | +15.9% | +5.9% |